Prospective Follow-up After MVA-BN Booster Vaccination
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Monkeypox (Mpox). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Belgium
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prospective On-site Study for the Immunological Follow-up of Individuals Who Received Booster Vaccination With MVA-BN Against Mpox
Overview
POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years.
Detailed description
Mpox caused a worldwide outbreak in 2022 and continues to circulate worldwide and causes sporadic cases in Belgium and elsewhere. In the last 10 days, the first cases infected with the probably more virulent clade Ib MPXV have been reported from men who have sex with men in Belgium, the Netherlands, and elsewhere, indicating circulating this viral clade in sexual networks. In Belgium, vaccination against mpox was ceased at the end of 2022 and evidence showed that antibody levels against MPXV have decreased since then, raising questions about sustained protectiveness and the potential for a new mpox outbreak to emerge.
POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years.
Primary outcome measures
- Orthopoxvirus-specific serum binding and neutralising antibody titre [Time frame: from enrollment to the end of follow up at 2 years]
Secondary outcome measures (2)
- Orthopoxvirus-specific systemic T- and B cell-mediated immune responses to MPXV [Time frame: from enrollment up to 2 years]
- MPXV-specific IgA in saliva and anorectal samples; T and B cell-mediated immune responses to MPXV, measured on saliva and anorectal samples [Time frame: from enrolment up to two years]
Eligibility criteria
Inclusion criteria
- Is scheduled to receive a booster dose of MVA-BN
- ≥18 years
- Willingness to provide written informed consent
- Willingness to follow the study schedule
Exclusion criteria
1\. Past or current MPXV infection
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Belgium · 1 center
- Institute of Tropical Medicine — Antwerp
Identifiers
NCT: NCT07342829 · POQS-Boosted